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Production
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Rafael R. Segura Muñoz 1, Liz A. Cody 1, Robert J. Schmaltz 1, Laure B. Bindels 1,
Rohita Sinha 1, Jesse M. Hostetter 2, Andrew K. Benson 1 and Amanda E. Ramer-Tait 1*
1Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, NE, United States, 2Department of
Veterinary Pathology, Iowa State University, Ames, IA, United States
Escherichia coli is a facultative anaerobic symbiont found widely among mammalian
gastrointestinal tracts. Several human studies have reported increased commensal
E. coli abundance in the intestine during inflammation; however, host immunological
responses toward commensal E. coli during inflammation are not well-defined. Here,
we show that colonization of gnotobiotic mice with different genotypes of commensal
E. coli isolated from healthy conventional microbiota mice and representing distinct
populations of E. coli elicited strain-specific disease phenotypes and immunopathological
changes following treatment with the inflammatory stimulus, dextran sulfate sodium
(DSS). Production of the inflammatory cytokines GM-CSF, IL-6, and IFN-γ was a hallmark
of the severe inflammation induced by E. coli strains of Sequence Type 129 (ST129)
and ST375 following DSS administration. In contrast, colonization with E. coli strains
ST150 and ST468 caused mild intestinal inflammation and triggered only low levels of
pro-inflammatory cytokines, a response indistinguishable from that of E. coli-free control
mice treated with DSS. The disease development observed with ST129 and ST375
colonization was not directly associated with their abundance in the GI tract as their levels
did not change throughout DSS treatment, and no major differences in bacterial burden
in the gut were observed among the strains tested. Data mining and in vivo neutralization
identified IL-6 as a key cytokine responsible for the observed differential disease severity.
Collectively, our results show that the capacity to exacerbate acute intestinal inflammation
is a strain-specific trait that can potentially be overcome by blocking the pro-inflammatory
immune responses that mediate intestinal tissue damage.
Keywords: commensal E. coli, intestinal inflammation, interleukin-6, strain-specific immune responses,
gnotobiotic mice
INTRODUCTION
The mammalian gut harbors a wide variety of bacteria (i.e., the gastrointestinal microbiota)
that coexist in a mutually beneficial state with their host (1). In this symbiotic relationship, the
microbiota contributes to nutrient degradation and metabolism, acts as a barrier that confers
resistance to pathogen colonization and helps develop and maintain proper immune responses
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(2–4). In return, the host provides the niches and nutrients
essential for microbial propagation and population survival.
Disruption of this homeostatic relationship, which occurs during
enteric infection or inflammation, can result in robust and
potentially pathogenic immune responses that are thought to
drive disease pathogenesis (5). This altered state of homeostasis
often manifests as a contraction of the highly-abundant obligate
anaerobic bacteria belonging to the Firmicutes and Bacteroidetes
and a corresponding outgrowth of Proteobacteria, including
members of family Enterobacteriaceae (6–8).
Among all Enterobacteriaceae, Escherichia coli is the
most widely-found facultative anaerobe in mammals (9). A
considerable degree of phylogenetic diversity has evolved
within the species E. coli, with some lineages acquiring various
combinations of virulence genes that enable them to adopt
overtly pathogenic lifestyles (10). Consequently, populations of
E. coli can engage in a variety of host interactions, ranging from
virulence to mutualism and even protection against infection
(11, 12). Even among lineages not known to be primarily
pathogenic, phenotypes can also range from the capacity to
protect against invading enteric pathogens to exacerbation of
inflammation induced by a variety of stimuli (11). With respect
to the former, the gut isolate E. coli EM0 strain and even the
JM105 cloning host strain can each protect against Salmonella
Typhimurium infection in germ-free mice (13). E. coli Nissle
1917 was also reported to protect against S. Typhimurium
infection, specifically by competing for iron availability (14).
In contrast, the pathobiont E. coli LF82 can function as a
benign member of the microbiota, but also has the capacity to
exacerbate intestinal inflammation in TLR5−/− mice (15). These
contrasting traits of protection versus pathobiont have not been
systematically studied across the population structure of E. coli.
Indeed, what differentiates a strain with pathobiont
characteristics (such as LF82) from those without is not
well-understood. Moreover, only a very small number of
isolates have been characterized with pathobiont phenotypes.
To gain insight into the strain-specific nature of the pathobiont
phenotype, we studied four gut commensal E. coli strains
isolated randomly from healthy conventional microbiota mice.
All isolates were derived from independent animals and,
by genotyping, represented independent multi-locus sequence
typing (MLST) lineages. When these strains were introduced into
gnotobiotic C3H/HeN mice bearing the altered Schaedler flora
(ASF), subsequent treatment with the inflammatory stimulus
dextran sulfate sodium (DSS) revealed that only two of the strains
tested had the capacity to exacerbate inflammatory responses.
Specifically, CEC-1 (ST129) or SWW33 (ST375)-colonized mice
developed severe intestinal disease characterized by increased
production of the pro-inflammatory cytokines granulocyte-
macrophage colony-stimulating factor (GM-CSF), interleukin-6
(IL-6), and interferon-gamma (IFN-γ). In contrast, mice
colonized with CEC-7 (ST150) or CEC-8 (ST468) experienced
only mild or no intestinal inflammation that was comparable
to DSS-treated control mice harboring no E. coli. Importantly,
neutralization of IL-6 production in vivo ameliorated E. coli
ST375-mediated disease. Altogether, our results demonstrate
strain-specific effects of commensal E. coli in the exacerbation of
TABLE 1 | MLST, conventional serotyping and phylogrouping of E. coli strains
used in this study.
E. coli
strain
Sequence
type (ST)
O
serotype
H
type*
Phylogroup** Source
CEC-1 129 2 6 B2 This study
CEC-7 150 120 1 B2 This study
CEC-8 468 1 + B1 This study
SWW33 375 110 + B2 Michael
Wannemuehler
CEC, commensal E. coli.
*+ for H type indicates fliC gene present but RFLP pattern does not match known patterns.
**E. coli phylogroup was determined for each strain using triplex PCR described by
Clermont et al. (16). based on the presence/absence of three genes (chuA, YjaA,
TspE4.C2).
acute inflammation and development of the pro-inflammatory
immune responses that drive intestinal tissue damage.
METHODS
Bacterial Strains
Four E. coli strains were isolated from the feces of specific
pathogen-free, healthy conventional microbiota mice and are
described in Table 1. Strain SWW33 was a kind gift from Dr.
Michael Wannemuehler at Iowa State University. Strains CEC-
1, CEC-7, and CEC-8 were isolated from mice housed at the
University of Nebraska-Lincoln. For E. coli strain isolation,
fecal pellets were resuspended in sterile 1X PBS (HyClone,
Logan, Utah, USA), plated on Eosin Methylene Blue (EMB)
agar plates (Difco, Sparks, MD, USA) and incubated for 24 h
at 37◦C. Individual colonies were biochemically analyzed for
E. coli identification as previously descried (17). All strains
were stored in Brucella broth (Difco) with 20% (v/v) glycerol
(Thermo FisherScientific, Middletown, PA, USA) at −80◦C. To
further characterize these four strains and determine whether
they were derived from unique populations, the strains were
subjected to O and H serotyping using either antisera generated
against each E. coli O-serogroup or PCR-RFLP analysis for H
typing, respectively, as previously described (18, 19). Strains were
also analyzed by multilocus sequence typing (MLST) utilizing
the sequences of eight housekeeping genes as described in the
Pasteur E. coli MSLT scheme (20). Allelic sequences at the eight
loci were then used to define the sequence type (ST) of each
isolate (21). E. coli phylogrouping for each strain was determined
using the triplex PCR described by Clermont et al. (16). For
mouse experiments, E. coli strains were plated on EMB agar
plates, grown overnight at 37◦C and used to inoculate autoclaved
Luria Bertani (LB) broth composed of 5 g bacto tryptone (Difco),
2.5 g yeast extract (Difco) and 5 g sodium chloride (Thermo
FisherScientific) dissolved in 500mL deionized water. Cultures
were grown overnight at 37◦C without shaking. The next day,
1mL of each overnight culture was transferred to a fresh 10mL
culture of LB broth and incubated at 37◦C for 4–6 h (to late log
phase) with shaking at 200 rpm. Bacterial cultures were then
centrifuged and resuspended at an approximate concentration of
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1 × 108 colony forming units (CFU) in 200 µL of LB broth for
oral gavage.
Mice
Eight-to ten-week-old male and female C3H/HeN mice
harboring the altered Schaedler flora (ASF) from birth were bred
and maintained under gnotobiotic conditions at the University
of Nebraska-Lincoln Gnotobiotic Mouse Facility. Members of
the ASF community include: ASF 356, Clostridium sp.; ASF
360, Lactobacillus intestinalis; ASF361, Lactobacillus murinus;
ASF 457, Mucispirillum schaedleri; ASF 492, Eubacterium
plexicaudatum; ASF 500, Pseudoflavonifractor sp.; ASF 502,
Clostridium sp.; and ASF 519, Parabacteroides goldsteinii (22).
All mice were raised in flexible film isolators and, immediately
prior to inoculation with E. coli strains, were transferred to
a positive-pressure individual ventilated caging (IVC) system
(Allentown Inc., Allentown, NJ, USA) and maintained as
previously described (23).
ASF-bearing mice were inoculated via oral gavage with 108
CFU of one of four commensal E. coli strains in 200 µL
of LB broth. Ten days later, feces were collected from all
mice, homogenized in sterile PBS, plated on EMB agar and
incubated overnight at 37◦C to check for successful E. coli
colonization and to confirm the absence of E. coli in control
mice. Intestinal inflammation was induced in mice by providing
2.5% (w/v) dextran sulfate sodium salt (DSS; MW = 36,000–
50,000, MP Biomedicals, Solon, OH, USA) in drinking water for
5 consecutive days as previously described (23). This treatment
was followed by a recovery period where mice received regular
drinking water for 4 days prior to necropsy. All procedures
involving animals were approved by the Institutional Animal
Care and Use Committee at the University of Nebraska-Lincoln
(Protocols 817 and 1215).
Bacterial Counts
E. coli colonization levels were assessed as previously described
(24). Feces were collected from mice on day 0 (prior to starting
DSS treatment), on day 5 (after completing DSS treatment),
and on day 9 (one day prior to necropsy). Fecal samples were
homogenized, diluted with sterile 1X in a series of 10-fold serial
dilutions and plated on EMB agar in 10 µL volumes in triplicate.
Plates were incubated at 37◦C for 24 h, and the colony-forming
units (CFU) present in each 10 µL drop were counted, averaged
among the triplicates and the data expressed as log10 CFU/g of
feces.
Macroscopic and Histopathological Scores
Macroscopic inflammatory changes in the cecum were scored at
necropsy as previously described (23, 25, 26). Macroscopic scores
were assigned on a scale of 0 or 1 for the absence or presence,
respectively, of each of the following criteria: cecal atrophy,
enlarged cecal tonsil, emptying, presence of mucoid or watery
contents, and presence of luminal blood in cecum. Individual
scores were combined to generate a gross cecal score (maximum
score of 5). For histopathological analysis, cecal tissues were
collected at necropsy and fixed in 10% neutral buffered formalin
(Thermo Fisher Scientific). Fixed tissues were then embedded
in paraffin, sectioned, and stained with hematoxylin and eosin
(H&E) at the Iowa State University Comparative Pathology
Core (Ames, IA). Tissues were scored in a blinded fashion
by a board-certified veterinary pathologist (JMH) based upon
previously published parameters (23, 25, 26), which included
mucosal height, gland hyperplasia, stromal collapse, edema,
inflammation, and ulceration. Each parameter was scored on
a scale of 0–5 according to the degree of severity and used to
generate a total histopathological score ranging from 0 (no score)
to 30 (maximum histopathological lesion score).
Cecal Explant Culture and Cytokine
Measurement
All reagents were obtained from Corning except for the 2-
Mercaptoethanol solution, which was purchased from Thermo
Fisher Scientific. For explant cultures, cecal tissues were prepared
as previously described (23, 24). Culture supernatants were
collected and stored at −20◦C until analysis. Chemokine
and cytokine levels in explant supernatants were measured
using customized Mouse Cytokine/Chemokine Milliplex
Magnetic Bead Kits (Millipore, Billerica, MA, USA) and a
MAGPIX instrument (Luminex Corporation, Austin, TX,
USA) according to the manufacturer’s instructions. Please see
Supplementary Material for methods describing cell culture,
infection assays, isolation of intestinal epithelial and lamina
propria cells, and flow cytometric analyses.
In vivo IL-6 Neutralization
Mice received an intraperitoneal injection of 300 µg of either
anti-IL-6 mAb (clone MP5-20F3) or rat IgG1 isotype control
(clone TNP6A7) 1 h prior to DSS treatment (day 0). Injections
were repeated on day 2, 4, 6, and 8. Injections were delivered in
a volume of 200 µL dilution buffer. All reagents were purchased
from Bio X Cell (West Lebanon, NH, USA).
Statistical and Computational Analyses
A portion of the analyses were performed using GraphPad Prism
6 (version 6.01, 2012, GraphPad Software, CA, USA). Data
analyzed via those methods are presented as mean± SEM. Non-
normally distributed data were analyzed using a non-parametric
Kruskal–Wallis test followed by unpaired Mann–Whitney post-
hoc test unless stated otherwise in figure legends. For all
experiments, p < 0.05 was considered statistically significant
(∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p <0.0001).
To assess which cytokine was the best predictor of severe
disease, a binary classification (0 or 1), was inserted into
the dataset. Specifically, E. coli ST129-DSS and ST325-DSS
treatments were classified as 1 and the remaining treatments as
0. The choice of classification was based on the results of cecal
gross and histopathological scores, which together demonstrated
that the E. coli ST129-DSS and ST325-DSS treatments induced
severe disease. This approach allowed for the application of
supervised machine learning methods and logistic regression
models to identify the best predictors of disease. Initial screening
for potential predictors was done using pairwise Spearman
correlation coefficients (p < 0.001) to identify the cytokines that
were significantly and positively associated with disease (i.e.,
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cecal gross and histopathological scores). The correlation matrix
was produced using the cor.mtest function() and corrplot ()
packages. Then, Random Forest [randomForest() package] and
binomial model-based [glmulti() package] searching algorithms
were used to identify the best predictors of disease using the
binary outcome. The Random Forest selection of the most
important biomarker was done based on the highest value
for the decreased mean in the Gini coefficient. The binomial
algorithm randomly iterated through combinations of models,
including all or subsets of cytokines until it converged to a
final, best-predictive model based on the Bayesian Information
Criteria (BIC). BIC was used for model selection to identify
the most parsimonious solution across all sets of estimated
models.
FIGURE 1 | Exacerbation of intestinal inflammation by commensal E. coli isolates was strain-specific. (A) Gross cecal lesion scores for control C3H/HeN ASF mice or
mice colonized with either E. coli ST150, ST468, ST375, or ST129 for 3 weeks (n ≥ 10, each group). DSS-treated mice received 2.5% DSS in their drinking water for
5 days and then regular water for 4 days. All mice were euthanized at day 10. (B) Histopathological cecal lesion scores for mice described in (A) (n = 5–10 animals
per group). Scoring parameters included mucosal height, epithelial cell ulceration, severity of inflammatory cell infiltrate, edema, stromal collapse, and goblet cell
depletion. (C) Representative cecum photomicrographs (H&E stained) were taken at x20 objective magnification. (A,B) Data were analyzed using a non-parametric
Kruskal–Wallis test followed by an unpaired Mann–Whitney post-hoc test. Values represent the mean ± the SEM. Treatments with different letters are significantly
different from one another at P < 0.05. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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After selecting the best model (which only included IL-6
as the predictor variable) based on both the Random Forest
and logistic regression procedures, a generalized mixed model
approach using a binomial distribution (link = logit) was used
to estimate the probability of disease for the two treatments
[glm() function]. The differences in probabilities between the
treatments classified as either 0 or 1 were tested using the
Welch two-tailed T-test (p < 0.05) [t.test() function]. The overall
accuracy of this model was calculated using a cross-validation
approach combined with a ROC analysis [ROCR() package].
These analyses were performed with R software, version 3.4.3
(R Core Team 2016, R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Exacerbation of Intestinal Inflammation by
Commensal E. coli Isolates Was
Strain-Specific
To evaluate the disease-causing potential of commensal E. coli
strains, gnotobiotic C3H/HeN mice harboring the altered
Schaedler flora (ASF) were colonized with one of four gut
commensal E. coli strains for 3 weeks prior to inducing
acute intestinal injury with 2.5% DSS. We selected ASF
mice for these studies because they contain a microbiome
devoid of any Proteobacteria and can be stably colonized
with E. coli without the need for antibiotic pretreatment.
Control ASF mice (no E. coli) and ASF mice colonized with
either E. coli ST150 or ST468 exhibited no to mild visible
cecal inflammation when exposed to 2.5% DSS. In contrast,
colonization with E. coli strains ST129 or ST375 caused
severe cecal disease characterized by cecal atrophy and the
presence of luminal blood (Figure 1A). Microscopic analysis
of cecal tissues confirmed the differential disease phenotypes
observed macroscopically (Figure 1B). In particular, lesions
from mice colonized with either E. coli ST129 or ST375 and
treated with DSS were characterized by extensive epithelial
ulceration, submucosal and mucosal edema, neutrophilic,
and monocytic cell infiltration, gland hyperplasia and stromal
collapse (Figure 1C). Consistent with macroscopic observations,
mice receiving either DSS only or E. coli strains only (but not
both) developed minimal microscopic lesions (Figures 1B,C).
Together, these results demonstrate that commensal E. coli
populations have strain-specific, disease-causing potentials
during intestinal inflammation.
The Abundance of Commensal E. coli
Strains Did Not Change During Intestinal
Inflammation and Was Not Associated
With Disease Severity
Several studies have reported that increases in the abundance
of Enterobacteriaceae, including E. coli, often occur during
intestinal inflammation (27–29). To determine whether the
enhanced intestinal inflammation caused by E. coli ST129 and
ST375 was accompanied by an increase in their abundance, all
E. coli strains were quantified in the feces of mice immediately
prior to initiating DSS treatment (day 0), after DSS treatment
(day 5), and one day prior to necropsy (day 9). Across all
time points evaluated, the average abundance of each E. coli
strain ranged from 108 to 109 (Figure 2). Further, levels of
E. coli ST129 (disease-causing) and ST150 (no disease) were
not significantly different from one another. An evaluation of
FIGURE 2 | The abundance of commensal E. coli strains did not change during intestinal inflammation. Feces were collected form all E. coli-colonized mice on day 0
(before DSS treatment), day 5 (after DSS treatment), and day 9 (day before necropsy), homogenized and serially-diluted in sterile PBS. Bacterial abundance was
determined by plating on EMB agar and incubating at 37◦C for 24 h. Each dot represents an individual animal (n = 15–17). Values were log10 transformed and data
are shown as mean ± SEM. A non-parametric Kruskal–Wallis test followed by unpaired Mann–Whitney post-hoc test were used to analyze data from multiple
treatments at each time point separately (day 0, day 5, and day 9). The same analysis was performed to analyze data from multiple time points for the same treatment.
Treatments with different letters are significantly different from one another at P < 0.05.
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FIGURE 3 | Strain-specific mucosal pro-inflammatory responses were observed during intestinal injury of mice colonized with commensal E. coli isolates. Cecal
explant tissues from control ASF mice or ASF mice colonized with either commensal E. coli ST150, ST468, ST375, or ST129 were cultured overnight. Supernatants
from these cultures were assessed by a magnetic multiplex assay (n = 5–16 animals per group) for levels of (A) GM-CSF, (B) IL-6, (C) IFN-γ, (D) IL-1β, (E) IL-17A, and
(F) IL-33. All data were analyzed by a non-parametric Kruskal–Wallis test followed by unpaired Mann–Whitney post-hoc test. Values represent the mean ± SEM.
Treatments with different letters are significantly different from one another at P < 0.05. *P < 0.05, **P < 0.01.
each strain’s abundance both before and after DSS exposure also
revealed no significant changes except for a slight decrease in
the abundance of ST129 (disease-causing) at necropsy (Figure 2).
Altogether, these findings demonstrate that commensal E. coli-
mediated intestinal inflammation was not associated with notable
increased abundances of these strains either prior to or after DSS
exposure.
Strain-Specific Mucosal Pro-inflammatory
Responses Were Observed During
Intestinal Injury of Mice Colonized With
Commensal E. coli Isolates
Because disease development was found to be independent of
E. coli abundance, we hypothesized that the exacerbated intestinal
inflammation caused by E. coli ST129 and ST375 was instead
due to the induction of a more robust pro-inflammatory host
immune response during intestinal injury compared to ST150
and ST468. To address this possibility, levels of cytokines were
evaluated in cecal explant cultures. FollowingDSS exposure, cecal
explants from mice colonized with either E. coli ST129 or ST375
(disease-causing) produced significantly higher levels of the pro-
inflammatory cytokines GM-CSF, IL-6, and IFN-γ compared to
control mice or mice colonized with ST150 or ST468 (no disease)
(Figures 3A–C). Cecal explants from mice colonized with E. coli
ST375 and treated with DSS also secreted elevated levels of the
pro-inflammatory cytokines IL-1β, IL-17A, and IL-33 relative to
other treatments (Figures 3D–F).
Ex vivo analyses aimed at assessing the specific role of
intestinal epithelial cells (IEC) in pro-inflammatory cytokine
production revealed no differences in cytokine secretion from
CD45− EpCAM+ IEC sorted from the ceca of control and
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FIGURE 4 | Commensal E. coli strains induced production of similar pro-inflammatory cytokine profiles from intestinal epithelial cells. Purified intestinal epithelial cells
(CD45− EpCAM+) were sorted from ASF mice, either control or colonized with E. coli ST150 or ST375. Cells were cultured for 3 hr and the supernatants assessed for
levels of (A) IL-6, (B) IL-1β, (C) GM-CSF, and (D) KC using a magnetic multiplex assay (each dot is a pool of 2–3 mice). Values represent mean ± SEM. (B,C) Vertical
dashed lines represent assay detection level (0.64 pg/mL). Data were analyzed using a non-parametric Kruskal–Wallis test followed by unpaired Mann–Whitney
post-hoc test.
DSS-treated mice colonized with either E. coli ST150 or ST375
(Figure 4). Furthermore, in vitro infection of bone marrow-
derived macrophages with E. coli strains ST150 and ST375
induced comparable IL-6 and IL-1β production (Figure 5).
We next isolated CD45+ lamina propria cells from the ceca
of mice colonized with either E. coli ST150 or ST375 ±
DSS treatment. We observed both similar numbers of, and
pro-inflammatory cytokine production from, Ly6Clow CD11b+
phagocytic cells, Ly6Chigh CD11c+ CD11b− dendritic cells, and
Ly6Chigh CD11b+ recruited inflammatory monocytes (Figure 5
and Supplementary Figures S1–S3). Other analyses revealed
no detectible antigen-specific IFN-γ in cultures of purified
CD4+ T cells isolated from the mesenteric lymph nodes of
mice colonized with E. coli ± DSS treatment when stimulated
with antigens from the commensal E. coli strains or the
ASF community (Supplementary Figure S4). Together, these
results demonstrate that gut commensal E. coli strains can
induce differential mucosal cytokine production. However, such
differential responses are not attributable specifically to IEC,
monocytes or CD4+ T cells.
Mucosal IL-6 Production Best Predicted
Commensal E. coli-Mediated Intestinal
Inflammation
To determine which cytokine(s) produced by cecal explants
best predicted disease outcome, we combined results from
a Spearman correlation analysis with a Random Forest
and binomial algorithm BIC-based selection and model
estimation. Collectively, this approach allowed calculation
of disease probability associated with a given biomarker.
Correlation analysis identified several cytokines, including
IL-6, as significantly and positively correlated with disease
scores (Figure 6A). Supervised machine learning and searching
algorithms also identified IL-6 as the best predictor of disease
categorized as either 0 (no to mild disease) or 1 (moderate
to severe disease) (Figure 6B). Importantly, this binary score
was specifically chosen as a classifying variable to separate the
most severely diseased E. coli ST129- and ST375-colonized
mice treated with DSS from the other treatments. A binomial
model was then used to assess the relationship of IL-6 levels
on the probability of predicting disease. Elevated IL-6 levels in
cecal explants not only significantly affected disease prediction
(p = 0.025), but clearly increased the likelihood of disease
development in both E. coli ST129- and ST375-colonized
mice treated with DSS (categorized as 1) (Figure 6C). Finally,
cross-validation-based model estimation and ROC analysis
revealed an overall accuracy of 97.5% (specificity = 98.48%
and sensitivity = 92.86%) in classifying mice between the
two treatments (0 vs. 1) (Figure 6D). Together, these findings
demonstrate that during intestinal injury, pro-inflammatory
responses—especially IL-6 production—are associated with
commensal E. coli isolates capable of inducing severe disease.
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FIGURE 5 | Commensal E. coli strains elicited similar pro-inflammatory cytokine profiles from monocytes and antigen presenting cells. (A–C) Bone marrow-derived
macrophages (BMDM) were seeded and plated for 24 h prior to infection with E. coli strains at MOI 10 (A) Survival and replication of each strain was assessed by
lysing macrophages and plating on EMB agar plates. The percentage of intracellular bacteria was graphed relative to that obtained 1 h-post gentamicin treatment
(defined as 100%). (B,C) Culture supernatants from infected BMDM were analyzed to measure IL-6 and IL-1β levels via ELISA. Values are the mean of triplicate
samples ± SEM of at least two experiments. (D) Number of recruited inflammatory monocytes (Ly6Chigh CD11b+) in isolated CD45+ LP cells were determined by
flow cytometry. Levels of IL-1β (E) and IL-6 (F) present in culture supernatants of inflammatory monocytes were assessed by a magnetic multiplex assay (each dot is a
pool of 2–3 mice). Data are shown as the mean ± SEM. For (A–C), multiple unpaired t-tests were performed on each time point indicated. For (D–F), a
non-parametric Kruskal–Wallis test followed by unpaired Mann–Whitney post-hoc test was used to analyze the data. *P < 0.05.
IL-6 Blockade Attenuated Disease Severity
in Mice Colonized With E. coli ST375 and
Exposed to DSS
IL-6 has pleotropic immunological effects and can either promote
intestinal inflammation (30) or provide mucosal protection (31)
in different murine models of colitis. The elevated mucosal IL-
6 response observed following DSS treatment of E. coli ST129-
or ST375-colonized mice (but not in mice colonized with E. coli
ST150 or ST468), along with the computational prediction,
suggests a pivotal role for this cytokine in disease progression.
To determine if IL-6 is functionally important in mediating
intestinal inflammation, mice colonized with either E. coli ST150
or ST375 were injected intraperitoneally with either an anti-IL-
6 monoclonal or rat IgG isotype control antibody prior to and
during DSS exposure. Neutralization of IL-6 by the monoclonal
antibody significantly reduced the severity of disease observed in
E. coli ST375-colonizedmice exposed toDSS compared to isotype
control-treated mice (Figure 7). Strikingly, the macroscopic and
microscopic disease scores for anti-IL-6 treated mice were
comparable to mice colonized with non-disease-causing E. coli
ST150 and exposed to DSS (Figures 7A–C), suggesting that
IL-6 is a major driver of the disease response. In contrast,
both anti-IL-6- and isotype control-treated mice colonized with
E. coli ST150 and exposed to DSS failed to develop disease.
An analysis of cecal explant cultures and serum from E. coli
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FIGURE 6 | Mucosal IL-6 production best predicted E. coli ST129- and ST375-mediated intestinal inflammation. (A) Spearman correlation plot depicting all pairwise
correlations between cytokines/chemokines and disease scores. The darker the shade of blue and the thinner the ellipse, the stronger the correlation coefficient.
Correlation coefficients were considered to be significant at p < 0.001 to account for multiple comparisons. (B) Random forest analysis was used to assess which
cytokine was the best sole predictor of disease occurrence when grouping all treatments as either 0 (no to mild disease) versus 1 (moderate to severe disease).
Specifically, E. coli ST129-DSS and ST325-DSS treatments were classified as 1 and the remainder treatments as 0. The strongest biomarker of disease was
determined based on the highest mean decrease in the Gini coefficient. (C) Results from a binomial model using IL-6 as the independent variable to predict the
probability of disease using the binary classification described above in (B) (i.e., 0 or 1 for the dependent variable). Plot shows a significant increase in the probability
of disease for E. coli ST129-DSS and ST325-DSS treatments (p = 0.025). (D) Cross-validation analysis to determine the accuracy of the binomial model for classifying
between groups coded as either 0 or 1 when using IL-6 as the only predictor. ROC analysis shows an overall 97.5% accuracy of the model-based classification
between the two treatments.
ST375 mice treated with anti-IL-6 and DSS revealed low to
undetectable levels of IL-6 when compared to their isotype
control counterparts (Figures 7D,E), suggesting successful local
and systemic blockade of IL-6 production. Taken together, these
results indicate that the differential production of IL-6 observed
during disease caused by distinct commensal E. coli strains does
play a critical biological role inmediating intestinal inflammation
following DSS administration.
DISCUSSION
Immune system-microbiota interactions are highly complex but
often confer mutual benefits to both the host and resident
microbes (3, 4). However, during an inflammatory insult, this
symbiotic alliance is altered and significant immunological
and microbiological changes occur that typically culminate in
immunopathology. Such alterations are often accompanied by
a loss of bacterial diversity and a corresponding bloom of one
or a few bacterial species, some of which may further aggravate
inflammation (5, 32). During this transition to an inflammatory
state, it is believed that species/strains with pathobiont potential
shift from being innocuous members of the microbiota to
effectors that further intensify the inflammation.
In the current study, we found that randomly chosen,
freshly isolated gut commensal E. coli strains displayed either
a neutral effect on inflammation induced by DSS or they
exacerbated inflammation, ultimately leading to overt disease.
The two strains with pathobiont characteristics appear to
drive inflammation largely through GM-CSF, IL-6, and IFN-γ
production—a cytokine signature known to actively contribute
to colitis progression (30, 33, 34). The importance of the
elevated cytokine profile observed in ST375- mediated intestinal
inflammation was tested by an in vivo neutralization experiment.
We focused on IL-6 neutralization to test this hypothesis based on
data mining techniques, which showed that among GM-CSF, IL-
6, and IFN-γ, IL-6 was the key cytokine that explained differential
disease severity induced by the E. coli strains. Neutralization of
IL-6 in vivo did indeed bring about significant improvements
in E. coli ST375-mediated intestinal inflammation. Based on
these findings, we propose that the elevated cecal levels of IL-
6 observed in DSS-exposed mice colonized by E. coli ST129
and ST375 are biologically relevant, and the capacity of these
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FIGURE 7 | IL-6 blockade attenuated disease severity in mice colonized with E. coli ST375 and exposed to DSS. (A) Gross cecal lesion scores depicting disease
severity in DSS-treated ASF mice colonized with either E. coli ST150 or ST375 and injected with either anti-IL-6 mAb or rat IgG isotype control. Mice received 300 µg
of either anti-IL-6 or rat IgG per injection on days 0, 2, 4, 6, and 8 of DSS treatment (n = 8–10 per group). Histopathological scores (B) were assessed based upon the
parameters described in Figure 1. (C) Representative photomicrographs of H&E stained tissues were taken at x20 objective magnification (n = 8–10 per group). IL-6
levels present in colonic explant cultures (D) and serum (E) were assessed by ELISA. Gross cecal score data were analyzed using a non-parametric Kruskal-Wallis
test followed by an unpaired Mann–Whitney post-hoc test. Histopathology scores and cytokine data were analyzed with a non-parametric unpaired Mann–Whitney
test. Values represent the mean ± SEM. Treatments with different letters are significantly different from one another at P < 0.05. **P < 0.01, ****P < 0.0001.
E. coli strains to elicit high levels of IL-6 plays a critical role
in promoting disease severity. Since we did not test in vivo
neutralization of the other elevated pro-inflammatory cytokines
(e.g., GM-CSF and IFN-γ), it remains entirely possible that
they may also play important roles in exacerbating intestinal
inflammation.
In our study, we were not able to pinpoint a specific cell
type responsible for the differential mucosal IL-6 production
observed among the E. coli strains we tested. This observation
may be partly explained by previous studies reporting that IL-
6 is produced by multiple cellular sources during colitis and
colorectal cancer (35, 36). Lamina propria mononuclear cells
isolated from colonic biopsies from ulcerative colitis and Crohn’s
disease patients released high levels of IL-6 when compared
to control subjects (37). CD11b+ lamina propria macrophages
have also been shown to be a source of IL-6 in DSS-treated
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BALB/c mice (38). Murine colonic epithelial cells also produce
high levels of IL-6 following infection with Citrobacter rodentium
(24, 31). Furthermore, Kuhn et al. have reported induction of IL-
6 by intraepithelial lymphocytes in mice transgenic for dominant
negative Tgfbr2 expressed in T cells and a knockout of the
IL10rb gene shortly after colitis development (36). Thus, it seems
likely that the elevated IL-6 levels result from production by a
consortium of immune and epithelial cells in mice colonized
with either E. coli ST129 or ST375 and exposed to DSS. We
also acknowledge that host genetics and the nature of the
inflammatory trigger could influence immune cell involvement,
cytokine profiles, and disease outcomes.
The exact characteristics of E. coli ST129 and ST375 that
trigger these cells to respond to the inflammatory stimuli and
synergistically exacerbate intestinal tissue damage during acute
inflammation remain to be identified. Abundance differences
can be eliminated as a factor, as the relative abundances of
ST129 and ST375 strains were not different than those of
ST150 and ST468. Although the cause-effect relationships are not
well-defined, a common general observation among microbial
imbalances during inflammatory states is decreased abundances
of taxa belonging to the Firmicutes and Bacteroidetes phyla
and the corresponding expansion of gram-negative bacteria
(i.e., Proteobacteria phylum), especially members of the family
Enterobacteriaceae (i.e., E. coli) (6, 7). Previous studies of
intestinal inflammation in particular often report expansions of
E. coli (28, 29). In contrast to these disease-associated blooms
of Enterobacteriaceae, differential disease outcomes mediated
by the ST129 and ST375 populations of E. coli tested in
our study were not a consequence of notable differences in
bacterial abundances. We observed similar E. coli colonization
levels for each strain during all conditions, suggesting no
direct association between disease severity and bacterial burden
in the gut under our experimental parameters. This result
may not be surprising since our gnotobiotic mice harbor a
minimal bacterial community, which allows each E. coli strain
to robustly colonize immediately upon introduction due to
niche availability. The absence of abundance differences as well
as the absence of abundance changes even after DSS-induced
inflammation suggests that the mechanisms through which
E. coli ST129 and ST375 exacerbate inflammation may instead
involve changes in gene expression patterns or metabolic activity.
Disease induction by pathobionts in the absence of abundance
changes has also been reported in Helicobacter pathobionts.
For example, H. bilis elicited intestinal inflammation and pro-
inflammatory immune responses directed against members of
the resident gut microbiota without increasing in abundance
(23). Similar observations have also been reported for H.
hepaticus (39). Thus, the capacity to induce immunopathological
effects without expanding during intestinal inflammation may be
a general feature of the pathobiont lifestyle, at least among the
Proteobacteria.
Several lineages of frank pathogens have evolved within
the species E. coli, mostly through acquisition of different
combinations of virulence genes (10). How the pathobiont
phenotype emerges in ST129 and ST375 is completely unknown.
Indeed, the phenomenon has only been studied in a relatively
small number of strains, and the pathobiont phenotype itself is
neither well-defined nor standardized across studies. Our data
in the ASF gnotobiotic mouse model shows that the phenotype
of exacerbating DSS-induced inflammation can be detected in
two distantly related populations of E. coli based on their
MLST sequence types. The shared phenotypic characteristics of
ST129 and ST375 include common histopathological features
and cytokine signatures, suggesting the phenotypes manifest
through similar mechanisms for both strains. If the mechanisms
are indeed similar, then the distant evolutionary relationship
of ST129 and ST375 implies that this particular pathobiont
phenotype may have emerged independently in each lineage.
Certainly, there is great need to understand the mechanism and
the genes/alleles that bring about this pathobiont phenotype.
Since we only examined a single strain of ST129 and ST375, it is
not even clear if the pathobiont phenotype is shared among all or
most strains of the clonal lineagesmarked by these STs.Moreover,
it is also unknown how widespread the phenotype may be among
the diverse populations of E. coli that have been identified.
Further supporting the idea that the pathobiont phenotype
may arise on multiple occasions are findings from others who
report both context-dependent and strain-specific differences in
the ability of E. coli isolates to either protect against or cause
disease. Oral administration of the putative probiotic E. coli
Nissle 1917 is documented to be protective during DSS-induced
colitis (40, 41). However, Nissle 1917 and E. coli K12 (a lab-
adapted strain) both exacerbated intestinal inflammation and
translocated to systemic organs in gnotobiotic C57BL/6j mice
infected with Toxoplasma gondii (42). NC101, a commensal
E. coli strain isolated from healthy mice, also exacerbated colitis
when monoassociated with germ-free IL-10−/− mice but not in
wild-type control animals (43). Collectively, these observations
demonstrate profound differential effects, both protective and
pathogenic, of E. coli strains during intestinal inflammation.
In conclusion, our findings extend the literature regarding the
strain-specific effects of E. coli by demonstrating the potential of
unique populations of E. coli isolated from healthy mice to cause
disease via differential induction of a pro-inflammatory cytokine
response that directly contributes to intestinal tissue damage.
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